Celldex Therapeutics CLDX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $15K-97.8% | $121K-89.7% | $0-100% | $730K-70.8% | $695K+346% | ||
| $73M+38.7% | $75.33M+60.5% | $62.93M+39.0% | $54.2M+36.6% | $52.61M+66.2% | ||
| $11.45M+5.8% | $11.94M+16.3% | $10.69M+6.3% | $10.39M+13.8% | $10.82M+18.9% | ||
| $854K-1.5% | $816K-0.4% | $824K+4.8% | $873K+9.5% | $867K+11.9% | ||
| $84.45M+33.1% | $87.27M+52.6% | $73.62M+33.1% | $64.59M+32.3% | $63.43M+55.6% | ||
| -$84.44M-34.6% | -$87.15M-55.6% | -$73.62M-41.2% | -$63.86M-37.9% | -$62.74M-54.5% | ||
| -562,900%-553,873pp | -72,027.3%-67,259pp | —— | -8,747.5%-6,893pp | -9,027.2%+17,004pp | ||
| $5.75M-35.7% | $5.84M-34.7% | $6.57M-34.3% | $7.26M-30.7% | $8.94M+14.7% | ||
| -$78.69M-46.3% | -$81.32M-72.7% | -$67.04M-59.2% | -$56.6M-57.9% | -$53.8M-64.0% | ||
| -524,566.7%-516,826pp | -67,204.1%-63,196pp | —— | -7,753.4%-6,319pp | -7,740.4%+13,290pp | ||
| -$1.18-45.7% | -$1.23-73.2% | -$1.01-57.8% | -$0.85-57.4% | -$0.81-44.6% | ||
| -$1.18-45.7% | -$1.23-73.2% | -$1.01-57.8% | -$0.85-57.4% | -$0.81-44.6% | ||
| 66.6M+0.3% | 66.4M+3.1% | 66.4M+0.2% | 66.4M+0.6% | 66.4M+12.8% | ||
| 66.6M+0.3% | 66.4M+3.1% | 66.4M+0.2% | 66.4M+0.6% | 66.4M+12.8% | ||
| -$79.79M-49.0% | -$81.46M-66.0% | -$66.62M-72.5% | -$56.83M-56.5% | -$53.54M-58.1% | ||
| $5.75M-35.7% | $5.84M-34.7% | $6.57M-34.3% | $7.26M-30.7% | $8.94M+14.7% | ||
| -$1.1M-535% | —— | $426K-87.9% | -$229K+50.6% | $254K+124% | ||
| $15K-97.8% | $121K-89.7% | $0-100% | $730K-70.8% | $695K+346% | ||
| -$84.44M-34.6% | -$87.15M-55.6% | -$73.62M-41.2% | -$63.86M-37.9% | -$62.74M-54.5% | ||
| -$83.58M-35.1% | -$86.34M-56.4% | -$72.79M-41.8% | -$62.98M-38.4% | -$61.87M-55.3% | ||
| -$83.58M-35.1% | -$86.34M-56.4% | -$72.79M-41.8% | -$62.98M-38.4% | -$61.87M-55.3% | ||
| -557,206.7%-548,304pp | -71,352.9%-66,654pp | —— | -8,627.9%-6,806pp | -8,902.4%+16,632pp | ||
| -$84.44M-34.6% | -$87.15M-55.6% | -$73.62M-41.2% | -$63.86M-37.9% | -$62.74M-54.5% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Celldex Therapeutics's revenue?
- Celldex Therapeutics (CLDX) generated $866.0K in revenue over the trailing twelve months, down 88.5% year over year.
- Is Celldex Therapeutics profitable?
- Celldex Therapeutics is not currently profitable: it reported a net loss of $283.6M over the trailing twelve months, a -32753.6% net margin.
- What is Celldex Therapeutics's earnings per share?
- Celldex Therapeutics's diluted EPS over the trailing twelve months is $-4.27.
- Where does Celldex Therapeutics's income statement data come from?
- Every line is extracted from Celldex Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
